<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02550106</url>
  </required_header>
  <id_info>
    <org_study_id>CIGE025EFR02</org_study_id>
    <nct_id>NCT02550106</nct_id>
  </id_info>
  <brief_title>Omalizumab in Chronic Spontaneous Urticaria Patients Non Responding to Initial Standard antihistaminE Treatment</brief_title>
  <acronym>SUNRISE</acronym>
  <official_title>A Phase IV, Multicenter, Single-arm and Open-label Study With Omalizumab (Xolair®) in Chronic Spontaneous Urticaria (CSU) Patients Who Remain Symptomatic Despite Antihistamine (H1) Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the proportion of patients with an urticaria control test [UCT] score of greater
      than or equal to 12 at Week 12.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>proportion of patients with an urticaria control test [UCT] score of greater than or equal to 12</measure>
    <time_frame>WEEK 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>proportion of patient with UAS7≤6 (patients achieving disease control), in adult patients with CSU, with or without the presence of angioedema</measure>
    <time_frame>WEEK 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CSU disease activity using the urticaria activity score (UAS7), with or without the presence of angioedema</measure>
    <time_frame>WEEK 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>control of the CSU using the UCT score, with or without the presence of angioedema</measure>
    <time_frame>WEEK 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The quality of life using the chronic urticaria quality of life (CU-QoL) questionnaire</measure>
    <time_frame>WEEK 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>angioedema activity using the angioedema activity score (AAS)</measure>
    <time_frame>WEEK 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The angioedema quality of life (AE-QoL)</measure>
    <time_frame>WEEK 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The dermatology life quality index (DLQI)</measure>
    <time_frame>WEEK 12</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>correlation between CSU disease control (UCT) and disease activity (UAS7 and AAS)</measure>
    <time_frame>WEEK 12</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>evolution of D-Dimer concentration</measure>
    <time_frame>WEEK 4, 8, 12</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>D-Dimer concentration based on the presence or absence of angioedema</measure>
    <time_frame>WEEK 4, 8, 12</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>correlation between D-Dimer concentration and CSU disease control (UCT)</measure>
    <time_frame>WEEK 12</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>correlation between D-Dimer concentration and disease activity (UAS7)</measure>
    <time_frame>WEEK 12</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>correlation between CSU disease control (UCT) and QoL (CU-QoL, AE-QoL and DLQI) measures</measure>
    <time_frame>WEEK 12</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">136</enrollment>
  <condition>CHRONIC SPONTANEOUS URTICARIA</condition>
  <arm_group>
    <arm_group_label>OMALIZUMAB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>sub cutaneous injections of 300 mg every 4 weeks until Week 8.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OMALIZUMAB</intervention_name>
    <description>sub cutaneous injections of 300 mg every 4 weeks until Week 8.</description>
    <arm_group_label>OMALIZUMAB</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients aged between 18 and 75 years.

          -  Diagnosis of CSU for ≥ 6 months and an inadequate response to nsH1 antihistamines at
             the time of the request, as defined by the following:

          -  The presence of itch and hives for &gt; 6 consecutive weeks at any time prior to
             enrollment, despite current use of H1 antihistamine therapy during this time period.

          -  Weekly UAS7 score (range 0 to 42) 16 and UCT score (range 0 to 16) &lt; 8 prior to
             enrollment (Day 1)

          -  Current use of an H1 antihistamine for CSU on the day of the initial visit and Day

          -  Informed consent

        Exclusion Criteria:

          -  Treatment with an investigational agent within 30 days before enrollment.

          -  Routine (daily or every other day during 5 or more consecutive days) doses of the
             following medications within 30 days prior to Day -7: systemic or cutaneous (topical)
             corticosteroids (prescription or over the counter), hydroxychloroquine, methotrexate,
             cyclosporine, or cyclophosphamide.

          -  Intravenous (i.v.) immunoglobulin G or plasmapheresis within 30 days prior to Day -7

          -  Regular (daily/every other day) doxepin (oral) use within 14 days prior to Day -7.

          -  Any H2 antihistamine use within 7 days prior to Day -7.

          -  Any leukotriene receptor antagonist (LTRA) (montelukast or zafirlukast) within 7 days
             prior to Day 7.

          -  Concomitant use of cyclosporine or any other immunosuppressive agent.

          -  Hypersensitivity to omalizumab or any component of the formulation.

          -  History of anaphylactic shock.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>CLAIRE BERNIER TAUGOURDEAU</last_name>
    <role>Principal Investigator</role>
    <affiliation>HOPITAL HOTEL DIEU - NANTES CEDEX 1</affiliation>
  </overall_official>
  <overall_official>
    <last_name>PASCAL JOLY</last_name>
    <role>Principal Investigator</role>
    <affiliation>HOPITAL CHARLES NICOLLE - ROUEN CEDEX</affiliation>
  </overall_official>
  <overall_official>
    <last_name>LUDOVIC MARTIN</last_name>
    <role>Principal Investigator</role>
    <affiliation>HOTEL DIEU - ANGERS CEDEX 9</affiliation>
  </overall_official>
  <overall_official>
    <last_name>GERARD GUILLET</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHR LA MILETRIE - POITIERS CEDEX</affiliation>
  </overall_official>
  <overall_official>
    <last_name>PATRICE PLANTIN</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHI DE CORNOUAILLE - QUIMPER CEDEX</affiliation>
  </overall_official>
  <overall_official>
    <last_name>ALAIN DUPUY</last_name>
    <role>Principal Investigator</role>
    <affiliation>HOPITAL PONTCHAILLOU - RENNES CEDEX 9</affiliation>
  </overall_official>
  <overall_official>
    <last_name>EVELYNE COLLET</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU SITE DU BOCAGE - DIJON CEDEX</affiliation>
  </overall_official>
  <overall_official>
    <last_name>ANNICK BARBAUD</last_name>
    <role>Principal Investigator</role>
    <affiliation>HOPITAUX DE BRABOIS - VANDOEUVRE LES NANCY CEDEX</affiliation>
  </overall_official>
  <overall_official>
    <last_name>ZIAD REGUIAI</last_name>
    <role>Principal Investigator</role>
    <affiliation>HOPITAL ROBERT DEBRE - REIMS CEDEX</affiliation>
  </overall_official>
  <overall_official>
    <last_name>FABIEN PELLETIER</last_name>
    <role>Principal Investigator</role>
    <affiliation>HOPITAL JEAN MINJOZ - BESANCON CEDEX</affiliation>
  </overall_official>
  <overall_official>
    <last_name>DELPHINE STAUMONT SALLE</last_name>
    <role>Principal Investigator</role>
    <affiliation>HOPITAL CLAUDE HURIEZ- LILLE CEDEX</affiliation>
  </overall_official>
  <overall_official>
    <last_name>JULIETTE JEGOU</last_name>
    <role>Principal Investigator</role>
    <affiliation>CH DE CHALONS EN CHAMPAGNE - CHALONS EN CHAMPAGNE CEDEX</affiliation>
  </overall_official>
  <overall_official>
    <last_name>EMMANUELLE AMSLER</last_name>
    <role>Principal Investigator</role>
    <affiliation>HOPITAL TENON - PARIS CEDEX 20</affiliation>
  </overall_official>
  <overall_official>
    <last_name>OLIVIER CHOSIDOW</last_name>
    <role>Principal Investigator</role>
    <affiliation>HOPITAL HENRI MONDOR - CRETEIL</affiliation>
  </overall_official>
  <overall_official>
    <last_name>VINCENT DESCAMPS</last_name>
    <role>Principal Investigator</role>
    <affiliation>HOPITAL BICHAT CLAUDE BERNARD - PARIS CEDEX 18</affiliation>
  </overall_official>
  <overall_official>
    <last_name>EMMANUEL MAHE</last_name>
    <role>Principal Investigator</role>
    <affiliation>CH VICTOR DUPOUY - ARGENTEUIL CEDEX</affiliation>
  </overall_official>
  <overall_official>
    <last_name>LILIANE LAROCHE</last_name>
    <role>Principal Investigator</role>
    <affiliation>HOPITAL AVICENNE - BOBIGNY CEDEX</affiliation>
  </overall_official>
  <overall_official>
    <last_name>GERMAINE GABISON</last_name>
    <role>Principal Investigator</role>
    <affiliation>HOPITAL SAINT LOUIS - PARIS CEDEX 10</affiliation>
  </overall_official>
  <overall_official>
    <last_name>SELIM ARACTINGI</last_name>
    <role>Principal Investigator</role>
    <affiliation>HOPITAL COCHIN - PARIS</affiliation>
  </overall_official>
  <overall_official>
    <last_name>LAURENCE BOUILLET</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU DE GRENOBLE - LA TRONCHE</affiliation>
  </overall_official>
  <overall_official>
    <last_name>JEAN-JACQUES GROB</last_name>
    <role>Principal Investigator</role>
    <affiliation>HOPITAL TIMONE - MARSEILLE CEDEX 05</affiliation>
  </overall_official>
  <overall_official>
    <last_name>FREDERIC CAMBAZARD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU SAINT ETIENNE - ST PRIEST EN JAREZ CEDEX</affiliation>
  </overall_official>
  <overall_official>
    <last_name>THIERRY BOYE</last_name>
    <role>Principal Investigator</role>
    <affiliation>HIA SAINTE ANNE - TOULON CEDEX 9</affiliation>
  </overall_official>
  <overall_official>
    <last_name>JEAN-PHILIPPE LACOUR</last_name>
    <role>Principal Investigator</role>
    <affiliation>HOPITAL DE L'ARCHET - NICE CEDEX 3</affiliation>
  </overall_official>
  <overall_official>
    <last_name>PHILIPPE BERBIS</last_name>
    <role>Principal Investigator</role>
    <affiliation>HOPITAL NORD- MARSEILLE</affiliation>
  </overall_official>
  <overall_official>
    <last_name>LAURENT MEUNIER</last_name>
    <role>Principal Investigator</role>
    <affiliation>HOPITAL CAREMEAU - NIMES CEDEX 9</affiliation>
  </overall_official>
  <overall_official>
    <last_name>FRANCOISE GIORDANO LABADIE</last_name>
    <role>Principal Investigator</role>
    <affiliation>HOPITAL LARREY - TOULOUSE CEDEX 9</affiliation>
  </overall_official>
  <overall_official>
    <last_name>NADIA RAISON PEYRON</last_name>
    <role>Principal Investigator</role>
    <affiliation>HOPITAL ST ELOI - MONTPELLIER CEDEX 5</affiliation>
  </overall_official>
  <overall_official>
    <last_name>MARIE CHRISTINE FERRIER LE BOUEDEC</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU ESTAING - CLERMONT FERRAND</affiliation>
  </overall_official>
  <overall_official>
    <last_name>MARIE SYLVIE DOUTRE</last_name>
    <role>Principal Investigator</role>
    <affiliation>HOPITAL DE HAUT LEVEQUE - PESSAC CEDEX</affiliation>
  </overall_official>
  <overall_official>
    <last_name>BRIGITTE MILPIED</last_name>
    <role>Principal Investigator</role>
    <affiliation>HOPITAL ST ANDRE - BORDEAUX CEDEX</affiliation>
  </overall_official>
  <overall_official>
    <last_name>CHRISTOPHE BEDANE</last_name>
    <role>Principal Investigator</role>
    <affiliation>HOPITAL DUPUYTREN - LIMOGES CEDEX 1</affiliation>
  </overall_official>
  <overall_official>
    <last_name>PHILIPPE MODIANO</last_name>
    <role>Principal Investigator</role>
    <affiliation>HOPITAL ST VINCENT DE PAUL - LILLE CEDEX</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Paris</city>
        <state>Cedex 10</state>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Angers</city>
        <zip>49033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Argenteuil</city>
        <zip>95107</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Besancon Cedex</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bobigny Cedex</city>
        <zip>93009</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bordeaux Cedex</city>
        <zip>33075</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chalons-en-Champagne</city>
        <zip>51005</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Clermont Ferrand cedex 1</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dijon</city>
        <zip>21034</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>LILLE Cedex</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Limoges cedex</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lyon cedex 04</city>
        <zip>69317</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Marseille Cedex 05</city>
        <zip>13885</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Montpellier cedex 5</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nantes</city>
        <zip>44035</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nice</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nimes Cedex</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Paris</city>
        <zip>75877</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Quimper</city>
        <zip>29000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Reims</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rennes Cedex 9</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saint-Etienne</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toulon Cedex 9</city>
        <zip>83800</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toulouse Cedex</city>
        <zip>31400</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vandoeuvre Les Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 9, 2015</study_first_submitted>
  <study_first_submitted_qc>September 11, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2015</study_first_posted>
  <last_update_submitted>March 20, 2016</last_update_submitted>
  <last_update_submitted_qc>March 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CHRONIC SPONTANEOUS URTICARIA, OMALIZUMAB, URTICARIA CONTROL TEST</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urticaria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Omalizumab</mesh_term>
    <mesh_term>Histamine Antagonists</mesh_term>
    <mesh_term>Histamine H1 Antagonists</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>January 10, 2017</submitted>
    <returned>February 28, 2017</returned>
    <submitted>November 8, 2017</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

